Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer

Sun,Shengjie; Shi,Weiwei; Wu,Zhiyong; Zhang,Guoqing; Yang,Bo; Jiao,Shunchang

doi:10.3892/etm.2015.2636

Prognostic significance of the mRNA expression of ERCC1, RRM1, TUBB3 and TYMS genes in patients with non-small cell lung cancer

Authors:
- Shengjie Sun
- Weiwei Shi
- Zhiyong Wu
- Guoqing Zhang
- Bo Yang
- Shunchang Jiao
View Affiliations

Affiliations: Department of Oncology, The General Hospital of People's Liberation Army, Beijing 100853, P.R. China
Published online on: July 15, 2015 https://doi.org/10.3892/etm.2015.2636
Pages: 937-941
Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study aimed to investigate the prognostic value of excision repair cross-complementing 1 (ERCC1), ribonucleotide reductase subunit M1 (RRM1), class III β‑tubulin (TUBB3) and thymidylate synthase (TYMS) in patients with non‑small cell lung cancer (NSCLC) receiving platinum‑based adjuvant chemotherapy. The mRNA expression of these genes was assessed in 72 tumor tissue samples obtained following surgery, using multiplex branched‑DNA technology. Subsequent to surgery, all 72 patients with NSCLC were treated with platinum‑based chemotherapy. The expression of these five genes was analyzed and the correlation with clinical characteristics and patient survival was investigated. Among the 72 samples, the incidence rate of mRNA expression of ERCC1 was 38.9% (28/72), RRM1 was 55.6% (40/72), TUBB3 was 47.2% (34/72) and TYMS was 62.5% (45/72). The incidence rate of ERCC1 expression in adenocarcinoma (34.2%) was significantly lower than that in non‑adenocarcinoma (44.1%; P<0.05). Furthermore, the incidence rates of TYMS and TUBB3 expression in the high‑median differentiation tissue samples were significantly lower than those in the low differentiation tissue samples (P<0.05). When the correlation of gene expression and patient survival was analyzed, high expression of ERCC1, RRM1, TUBB3 or TYMS was found to be associated with poor prognosis (P<0.001, P=0.001, P=0.001 and P=0.001, respectively). ERCC1, RRM1, TUBB3 and TYMS are key factors involved in survival following surgical treatment in patients with NSCLC. The mRNA expression of these genes may have prognostic value for patients with NSCLC treated with platinum-based chemotherapy.

View Figures

View References

1	Chen W, Zhang S and Zou X: Evaluation on the incidence, mortality and tendency of lung cancer in China. Thoracic Cancer. 1:35–40. 2010. View Article : Google Scholar
2	Jazieh AR, Bamefleh H, Demirkazik A, et al: MENA Lung Cancer Regional Guidelines Committee: Modification and implementation of NCCN guidelines on non-small cell lung cancer in the Middle East and North Africa region. J Natl Compr Canc Netw. 8(Suppl 3): S16–S21. 2010.PubMed/NCBI
3	Li J, Li ZN, Yu LC, et al: Association of expression of MRP1, BCRP, LRP and ERCC1 with outcome of patients with locally advanced non-small cell lung cancer who received neoadjuvant chemotherapy. Lung Cancer. 69:116–122. 2010. View Article : Google Scholar : PubMed/NCBI
4	Rosell R, Danenberg K, Alberola V, et al: Spanish Lung Cancer Group: Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients. Clin Cancer Res. 10:1318–1325. 2004. View Article : Google Scholar : PubMed/NCBI
5	Peters GJ, Backus HH, Freemantle S, et al: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim biophys Acta. 1587:194–205. 2002. View Article : Google Scholar : PubMed/NCBI
6	Azuma K, Sasada T, Kawahara A, et al: Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer. 64:326–333. 2009. View Article : Google Scholar : PubMed/NCBI
7	Burkhart CA, Kavallaris M and Band Horwitz S: The role of beta-tubulin isotypes in resistance to antimitotic drugs. Biochim Biophys Acta. 1471:O1–O9. 2001.PubMed/NCBI
8	Flagella M, Bui S, Zheng Z, et al: A multiplex branched DNA assay for parallel quantitative gene expression profiling. Anal Biochem. 352:50–60. 2006. View Article : Google Scholar : PubMed/NCBI
9	Ren GJ, Zhao YY, Zhu YJ, et al: Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer. Chin Med J (Engl). 124:19–25. 2011.PubMed/NCBI
10	Crinò L, Weder W, van Meerbeeck J and Felip E: ESMO Guidelines Working Group: Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 21(Suppl 5): 103–115. 2010. View Article : Google Scholar
11	Zheng Z, Chen T, Li X, et al: DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 356:800–808. 2007. View Article : Google Scholar : PubMed/NCBI
12	Lee KH, Min HS, Han SW, et al: ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer. 60:401–407. 2008. View Article : Google Scholar : PubMed/NCBI
13	Gurubhagavatula S, Liu G, Park S, et al: XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol. 22:2594–2601. 2004. View Article : Google Scholar : PubMed/NCBI
14	Zhou W, Gurubhagavatula S, Liu G, et al: Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res. 10:4939–4943. 2004. View Article : Google Scholar : PubMed/NCBI
15	Davidson JD, Ma L, Flagella M, et al: An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines. Cancer Res. 64:3761–3766. 2004. View Article : Google Scholar : PubMed/NCBI
16	Ceppi P, Volante M, Novello S, et al: ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 17:1818–25. 2006. View Article : Google Scholar : PubMed/NCBI
17	Sève P, Reiman T, Lai R, et al: Class III beta-tubulin is a marker of paclitaxel resistance in carcinomas of unknown primary site. Cancer Chemother Pharmacol. 60:27–34. 2007. View Article : Google Scholar : PubMed/NCBI
18	Sève P and Dumontet C: Is class III beta-tubulin a predictive factor in patients receiving tubulin-binding agents? Lancet Oncol. 9:168–75. 2008. View Article : Google Scholar : PubMed/NCBI
19	Ceppi P, Rapa I, Lo Iacono M, et al: Expression and pharmacological inhibition of thymidylate synthase and Src kinase in nonsmall cell lung cancer. Int J Cancer. 130:1777–1786. 2012. View Article : Google Scholar : PubMed/NCBI
20	Grimminger PP, Schneider PM, Metzger R, et al: Low thymidylate synthase, thymidine phosphorylase, and dihydropyrimidine dehydrogenase mRNA expression correlate with prolonged survival in resected non-small-cell lung cancer. Clin Lung Cancer. 11:328–34. 2010. View Article : Google Scholar : PubMed/NCBI
21	Nakagawa T, Otake Y, Yanagihara K, et al: Expression of thymidylate synthase is correlated with proliferative activity in non-small cell lung cancer (NSCLC). Lung Cancer. 43:145–149. 2004. View Article : Google Scholar : PubMed/NCBI
22	Zheng Z, Li X, Schell MJ, et al: Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer. Cancer. 112:2765–73. 2008. View Article : Google Scholar : PubMed/NCBI